Nav: Home

Researchers identify new drug target for gastrointestinal stromal tumors

November 01, 2016

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene. Results of the human study were recently published online in Oncotarget.

"Our new finding is a step forward in overcoming tyrosine kinase inhibitor resistance, a clinically significant problem in the management of GIST," said Jason Sicklick, MD, associate professor of surgery at UC San Diego School of Medicine and surgical oncologist at Moores Cancer Center at UC San Diego Health. "By knowing that Hedgehog signaling is altered in human GIST, and that it controls KIT expression, we may have found a way to turn the cancer off."

GISTs eventually become highly resistant to current drug therapies. Clinicians fight the growth with progressively aggressive drugs, the downside being that each later line of therapy has diminishing effectiveness and higher toxicity for patients. More than 95 percent of patients eventually succumb to drug-resistant GIST, necessitating the search for alternative therapeutic targets.

"We may have found this cancer's 'on' switch," said Sicklick. "We are flipping the switch 'off' with arsenic, a drug that is already in clinical practice. With this drug, we are able to kill multidrug-resistant cell lines, offering a new approach to treatment."

GIST is the most common sarcoma with an estimated annual incidence of 6.8 cases per million people in the United States. These tumors start in special cells found in the wall of the GI tract, called the interstitial cells of Cajal (ICCs). ICCs are sometimes called the "pacemakers" of the GI tract because they signal the muscles in the digestive system to contract to move food and liquid through the GI tract.

Sicklick was recently named by The Life Raft Group, a national advocacy group that supports research and treatment of GIST, as their Clinician-of-the-Year for 2016. As a physician-scientist, Sicklick is dedicated to understanding GIST at the basic science level while finding treatments for GIST that are best for adult, adolescent and pediatric patients. Tamas Ordog, MD, co-senior author of the paper, is a basic scientist known for his research on ICCs. He is affiliated with the Mayo Clinic Center for Individualized Medicine and he is a member of the Life Raft Group Research Team.
-end-
Moores Cancer Center is the region's only NCI-designated comprehensive cancer center. It is also the first and only San Diego-based member of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers. Moores Cancer Center currently operates more than 170 open treatment trials. These investigational therapies include advanced, highly personalized stem cell-based approaches and immunotherapies that leverage the inherent healing powers of the human body.

To learn more about the treatment of GIST at Moores Cancer Center, visit: https://health.ucsd.edu/specialties/cancer/programs/gastrointestinal/Pages/gist.aspx

Contributors to this paper include: Chih-Min Tang, Tracy E. Lee, Adam M. Burgoyne, Stephanie Y. Leonard, Jonathan C. Chan, Eileen Shi, Martina De Siena, and Olivier Harismendy from UC San Diego; Sabriya A. Syed, Fei Gao, Michael L. Kendrick, and Michael R. Bardsley from Mayo Clinic; Junhao Mao from University of Massachusetts, Worchester, Massachusetts; and Juliann Chmielecki, Deborah Morosini, Kai Wang, and Jeffrey S. Ross from Foundation Medicine Inc.

University of California - San Diego

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.